Merck Sharp + Dohme Corp.

Rudrajit Mal

Anthony K Ogawa

Scott D Edmondson

Santhosh Francis Neelamkavil

Weiguo Liu

Dong-Ming Shen

Hong Shen

Peter J Sinclair

Zhicai Wu

Richard Thomas Beresis

Zhuyan Guo

Alan W Hruza

Robert J DeVita

Wanying Sun

Tesfaye Biftu

Amjad Ali

Mark D Erion

Sung-Sau So

Xianhai Huang

Kun Liu

Jinlong Jiang

Fa-Xiang Ding

Haifeng Tang

Ying-Duo Gao

Helen Y Chen

Rongze Kuang

Yan Guo

Eric Mertz

Charles A Lesburg

Christopher W Plummer

Linda Brockunier

Weidong Pan

Yuguang Wang

Ellen K Vande Bunte

Ping Lan

Changhe Qi

Alejandro Crespo

Yi Zang

John Qiang Tan

Jiafang He

Zhongxiang Sun

Min Shu

Min K Park

Heping Wu

Remond Moningka

Zahid Hussain

Hongwu Wang

Andrew F Nolting

Helen Chen

Anthony Ogawa

Min Park

Santosh Neelamkavil

Robert J Devita

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, Q, A, M, W, Rand Rare as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

Factor XIa inhibitors

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein. 

The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.

Mineralocorticoid receptor antagonists

Disclosed are the compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, which are useful for treating aldosterone-mediated diseases. The processes for preparing compounds of the Formula (I), the use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and the pharmaceutical compositions which comprise compounds of the formula (I) are disclosed too. 

Growing community of inventors

Edison, NJ, United States of America

Rudrajit Mal